Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemacabtagene Ansegedleucel in LBCL with MRD After First Line Therapy
NCT06500273Phase 2Recruiting
- Sponsor
- Allogene Therapeutics
- Start
- Jun 2024
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 4
01
Overview
A Phase 2 trial of cemacabtagene ansegedleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Allogene Therapeutics. Started Jun 2024; status: recruiting.
02
Drugs
cemacabtagene ansegedleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06500273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06500273.